OncoMatch/Clinical Trials/NCT06947967
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Is NCT06947967 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) and Tucidinostat for lymphoma, t-cell, peripheral.
Treatment: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) · Tucidinostat — A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: lymphoma-targeted therapy
Received prior therapies targeting lymphoma
Cannot have received: cytotoxic drugs for another condition
Prior treatment with cytotoxic drugs for another condition (e.g., rheumatoid arthritis)
Cannot have received: investigational therapy
Any investigational therapy within 3 months
Lab requirements
Blood counts
Hemoglobin (Hb)≥90g/L, ANC ≥1.5×10^9/L, platelets ≥90×10^9/L
Kidney function
Serum creatinine ≤1.5×ULN
Liver function
Total bilirubin ≤1.5 × ULN, ALT/AST ≤2.5×ULN (ALT, AST≦5×ULN if liver involved)
Cardiac function
LVEF < 50% during screening, Grade II or higher congestive heart failure, unstable angina, MI within 6 months, arrhythmia requiring treatment, primary cardiomyopathy, history of significant QT interval prolongation, QTc≥450ms (male), QTc≥470ms (female), symptomatic coronary heart disease requiring treatment
Laboratory criteria are as follows except that caused by lymphoma assessed by the investigator (without receiving any supportive treatment for the following parameters within 2 weeks from the last dose prior to study entry): (1)Hematology values:Hemoglobin (Hb)≥90g/L,Absolute neutrophil count (ANC) ≥1.5×10 9/L, platelets ≥90×10 9/L (2)Biochemical values: Serum creatinine ≤1.5×upper limit of normal(ULN),Total bilirubin ≤1.5 × ULN, Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) ≤2.5×ULN(ALT, AST≦5×ULN if liver involved). Cardiac: see exclusion criteria for details.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify